Lipids and atherosclerosis: Clinical management of hypercholesterolaemia

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 3, 2001, Pages 419-430

  Chin Dusting, J P F ^a   Shaw, J A ^a  

^a NONE

Author keywords

Atherosclerosis; Bile acid resins; Fibrates; HMG CoA reductase inhibitors; Hypercholesterolaemia; Plant stanols; Statins

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID RESIN; CERIVASTATIN; CIMETIDINE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; COMPACTIN; CYCLOSPORIN; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; MEVINOLIN; NICOTINIC ACID; PHYTOESTROGEN; PHYTOSTEROL; PRAVASTATIN; PROBUCOL; RESIN; SIMVASTATIN; STANOL ESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ANEMIA; ARTHRALGIA; ATHEROSCLEROSIS; CONSTIPATION; DIET THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LEUKOPENIA; MALE; MORTALITY; MYOPATHY; MYOSITIS; NAUSEA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRURITUS; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; URTICARIA;

ARTERIOSCLEROSIS; CHOLESTYRAMINE; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; NIACIN; NUTRITION PHYSIOLOGY; PROBUCOL;

EID: 0035002927     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.3.419     Document Type: Review

References (67)

1. Influence of plaque configuration and stress distribution on fissuring atherosclerotic plaques
2. The relationship between coronary artery lesions and MIs: Ulceration of atherosclerotic plaques precipitating coronary thrombosis
3. The pathogenesis of coronary thrombosis
4. Why do plaques rupture?
5. Serum cholesterol lipoproteins and the risk of coronary heart disease
6. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361662 men
7. Coronary heart disease in seven countries
8. The diet and 15 year death rate in the seven countries study
9. Diet serum cholesterol and death from coronary heart disease: The Western Electric Study
10. Obesity as an independent risk factor for cardiovascular disease: A 26 year follow up of participants in the Framingham heart study
11. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
12. The effect of pravastatin on coronary events after Mlion in patients with average cholesterol levels
13. ML236A ML236B ML236C new inhibitors of cholesterogenesis produced by Penicillium citrininum
14. Competitive inhibition of 3-hydroxy 3-methylglutaryl coenzyme A reductase by ML 236A and ML 236B fungal metabolites having hypercholesterolaemic activity
15. Hypolipidaemic effects in dogs of ML 236B a competitive inhibitor of 3 hydroxy-3-methylglutaryl coenzyme A reductase
16. Cholesterol lowering effect of mevinolin, an inhibitor of 3-hydroxy-3 methylglutaryl coenzyme A reductase in healthy volunteers
17. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
19. Pravastatin therapy and the risk of stroke
20. Prevention of a first stroke. A review of guidelines and a multi-disciplinary consensus statement from the National Stroke Association
21. Current status of risk factors for stroke
22. Reduction of stroke incidence after Mlion with pravastatin
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
24. Expanded clinical evaluation of lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia
25. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
26. Lipid-lowering and plaque regression. New insights into previous incidents of plaque disruption and clinical events in coronary disease
27. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate
28. Lovastatin inhibits low-density oxidation and alters fluidity and uptake by macrophages: In vitro and in vivo studies
29. Oxidized LDL-induced leukocyte/endothelium interaction involves the receptor for platelet-activating factor
30. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques
31. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
32. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
33. Inhibition of proliferation of human smooth muscle cells by HMG CoA reductase inhibitors; comparison with other human types
34. Lipids and the endothelium
35. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
36. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model
37. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia
38. Effect of gemfibrozil in vitro on fat mobilising lipolysis in human adipose tissue
39. Helsinki Heart Study: Primary prevention trial with Gemfibrozil in middle aged men with dyslipidaemia
40. Influence of Lovastatin plus Gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia
41. Treatment of combined hyperlipidaemia with fluvastatin and gemfibrozil, alone or in combination does not induce muscle damage
42. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidaemia
43. The effect of treatment with clofibrate on hepatic triglyceride and lipoprotein lipase activities of post-heparin plasma in male patients with hyperlipidaemia
44. Clofibrate and niacin in coronary heart disease
45. Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol
46. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study
47. Effect of nicotinic acid on plasma lipids in patients with hyperlipoproteinaemia during the first week of treatment
48. Effects of lipolytic and antilipolytic substances on adenosine 3′5′ monophosphate levels in isolated fat cells
49. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism
50. Normalization of LDL levels in heterozygous familial hypercholesterolaemia with a combined drug regimen
51. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention study by combined treatment with clofibrate and nicotinic acid
52. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
53. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis
54. Effects of probucol on lipoprotein protein kinetics
55. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow of atherosclerosis in the Watanabe heritable hyperlipidaemic rabbit
56. Prevention of restenosis in small arteries with probucol
57. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects
58. Comparison of intestinal absorption of cholesterol with different plant sterols
59. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol
60. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester containing spread to statin therapy
61. Menopause and the risk of coronary heart disease in women
62. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
63. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
64. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in post menopausal women: The Postmenopausal Estrogen/Progestin Intervention (PEPI) trial
65. A comparison of estrogen replacement, pravastatin and combined treatment for the management of hypercholesterolaemia in postmenopausal women
66. Effects of estrogen replacement on the progression of coronary artery atherosclerosis
67. Antihypertensive, antiatherosclerotic and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1 adrenoceptor-blocking activity in experimental animals